Clinical Trial Update: Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 study of oral PHA-848125AC in patients with malignant thymoma was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thymoma

Drugs mentioned

• PHA-848125AC

Snippet

Sponsor: Tiziana Life Sciences LTD | Conditions: Malignant Thymoma | Phase 2 | Status: TERMINATED | Results posted: 2018-10-04